Celexa vs. Viibryd

See how Celexa and Viibryd compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Celexa and Viibryd both treat major depressive disorder in adults and both carry a boxed warning for increased suicidal thoughts in children and young adults.

  • Celexa is an SSRI with a simple two-week titration and much lower cost, while Viibryd is a SPARI with a three-step titration that must be taken with food.

  • Both drugs commonly cause nausea and insomnia, but Viibryd causes more diarrhea while Celexa causes more dry mouth and sedation.

Celexa vs. Viibryd Drug Summary

Celexa

Celexa (citalopram) is a selective serotonin reuptake inhibitor (SSRI) approved to treat major depressive disorder in adults. It comes as a tablet or oral solution taken once daily, starting at 20 mg and increasing to a 40 mg maintenance dose after one week. It has been available since 1998 and remains one of the most widely prescribed antidepressants.

Viibryd

Viibryd (vilazodone) is a serotonin partial agonist and reuptake inhibitor (SPARI) approved to treat major depressive disorder in adults. It's taken as a tablet once daily with food, titrated from 10 mg up to a 40 mg maintenance dose over two weeks. Approved in 2011, it works through a mechanism distinct from standard SSRIs.

Celexa vs. Viibryd Side Effects

Celexa

Most common
Nausea (21%)
Dry mouth (20%)
Insomnia (15%)
Somnolence (18%)

Viibryd

Most common
Nausea (up to 23%)
Dry mouth (up to 5%)
Insomnia (6% to 7%)
Diarrhea (up to 28%)

Celexa vs. Viibryd Dosage

Celexa

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 20 mg once daily Week 1
Maximum dose 40 mg once daily Week 2 onward
Dose changes 1 increase Every week

Viibryd

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg once daily Days 1-7
Maximum dose 40 mg once daily Day 15 onward
Dose changes 2 increases Every 7 days

Celexa vs. Viibryd Indications

Celexa

Celexa is FDA-approved to treat major depressive disorder in adults. Clinicians also prescribe it off-label for generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder. It is not approved for use in children or for bipolar depression.

  • FDA-approved for major depressive disorder in adults

  • Prescribed off-label for generalized anxiety disorder

  • Prescribed off-label for panic disorder

  • Prescribed off-label for obsessive-compulsive disorder

Viibryd

Viibryd is FDA-approved to treat major depressive disorder in adults. It has no widely recognized off-label uses and is not approved for pediatric depression. It must be taken with food for the medication to absorb properly.

  • FDA-approved for major depressive disorder in adults

  • Not approved for pediatric depression

  • No established off-label uses at this time

  • Requires food intake for proper absorption

Celexa vs. Viibryd Pros and Cons

Celexa

Celexa has an established long-term safety profile and is available as a low-cost generic, making it accessible for most patients. Its main clinical limitation is a dose-dependent QT prolongation risk, which caps the maximum dose and requires added caution in older adults. It remains a reasonable first-line choice for straightforward MDD, with off-label usefulness for anxiety-related conditions.

Pros

  • Available as an inexpensive generic tablet or oral solution

  • Decades of long-term safety data since its 1998 approval

  • Reaches full maintenance dose in just two weeks

  • Prescribed off-label for anxiety, panic disorder, and OCD

Cons

  • Carries a dose-dependent QT prolongation risk requiring caution

  • Maximum dose capped at 20 mg/day in older adults or poor metabolizers

  • Cannot exceed 40 mg/day, limiting dose flexibility

  • More likely to cause dry mouth and sedation than Viibryd

Viibryd

Viibryd offers a distinct SPARI mechanism that may suit patients who did not respond well to standard SSRIs, along with a milder anticholinergic side effect profile. Its main drawbacks are a longer titration schedule, a strict food requirement for absorption, and a significantly higher cost with no generic option. It functions more as a second-line choice for adults with MDD rather than a typical first pick.

Pros

  • Lower rates of dry mouth and sedation than Celexa

  • No dose reduction required based on age or liver function

  • Distinct SPARI mechanism, an option for SSRI non-responders

  • No QT-prolongation warning on its label

Cons

  • Longer three-step titration process before reaching full dose

  • Must be taken with food or absorption drops significantly

  • Higher rates of diarrhea and nausea than Celexa

  • No generic version widely available despite FDA generic approval

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.